Tuesday, May 19, 2020 8:40:19 AM
Ritter Pharmaceuticals, Qualigen All-Stock Merger Deal Gets Shareholder OK
08:37 AM EDT, 05/19/2020 (MT Newswires) -- Ritter Pharmaceuticals (RTTR) said Tuesday its all-stock merger deal with Qualigen has received approval from Ritter stockholders and should be consummated in the next few days.
Under the agreement, pre-merger Ritter Pharmaceuticals stockholders will own approximately 7.5% of the post-merger combined company. On the other hand, the pre-merger Qualigen stockholders will own approximately 92.5% of the post-merger combined company on a fully-diluted basis.
Prior to closing, the company will change its name to Qualigen Therapeutics and continue trading on Nasdaq Capital Market under the symbol "QLGN."
On a side note they did say before"Ritter stockholders should also be aware that they will not be subject to a lock-up period following the merger.”
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM